Nuvectis Pharma
NVCT
40 hedge funds and large institutions have $12.8M invested in Nuvectis Pharma in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 11 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
45% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 11
11% more funds holding
Funds holding: 36 → 40 (+4)
1% more capital invested
Capital invested by funds: $12.6M → $12.8M (+$188K)
0.06% more ownership
Funds ownership: 8.73% → 8.79% (+0.06%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$215K |
| 2 |
Morgan Stanley
New York
|
+$155K |
| 3 |
BZWA
Blue Zone Wealth Advisors
Los Angeles,
California
|
+$122K |
| 4 |
BWP
Baldwin Wealth Partners
Marion,
Massachusetts
|
+$103K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$102K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$214K |
| 2 |
Two Sigma Investments
New York
|
-$190K |
| 3 |
BlackRock
New York
|
-$129K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$31.7K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$17.7K |
NVCT Hedge Fund Activity: Q1 2024 in Review
40 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q1 2024, worth a combined $12.8M — up 1.5% from $12.6M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new NVCT positions and 2 closed out — a net gain of 4 holders — while 16 added to existing stakes and 11 trimmed.
The largest buyer was Marshall Wace, adding an estimated $215K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $214K sold.
- 40 institutional investors held Nuvectis Pharma (NVCT) as of Q1 2024, up from 36 in Q4 2023.
- Funds reported $12.8M of Nuvectis Pharma stock for Q1 2024, up 1.5% quarter-over-quarter.
- 6 funds opened new Nuvectis Pharma positions in Q1 2024 and 2 closed out, a net change of +4 holders.
- The largest Nuvectis Pharma buyer in Q1 2024 was Marshall Wace, an estimated $215K added.
- The largest Nuvectis Pharma seller in Q1 2024 was Susquehanna International Group, an estimated $214K sold.
Based on aggregated 13F filings for Q1 2024.